Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Future Sci OA
; 5(9): FSO421, 2019 Sep 25.
Article
em En
| MEDLINE
| ID: mdl-31608159
ABSTRACT
BACKGROUND:
We conducted a meta-analysis to evaluate the efficacy and safety of upfront add-on immunotherapy for advanced non-small cell lung cancers (NSCLC).METHODS:
We performed a literature search on first-line chemotherapy ± immunotherapy in NSCLC. We utilized Revman version 5.3 to calculate the estimated pooled hazard ratio for overall survival (OS) and progression-free survival (PFS) and pooled risk ratio for objective response rate (ORR), all-grade and high-grade adverse events with 95% CI.RESULTS:
We analyzed 4322 patients. The pooled hazard ratios for OS, PFS and ORR were 0.74 (95% CI 0.62-0.88; p = 0.0007), 0.62 (95% CI 0.57-0.68; p = 0.00001) and 1.51 (95% CI 1.3-1.74; p = 0.00001), respectively. The pooled risk ratios for all-grade and high-grade adverse events were 1.01 (95% CI 0.99-1.03; p = 0.27) and 1.17 (95% CI 1.07-1.28; p = 0.0006), respectively.CONCLUSION:
Add-on immunotherapy significantly improves PFS, OS and ORR for the first-line treatment of advanced NSCLC with a reasonable safety profile.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Idioma:
En
Revista:
Future Sci OA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos